A Prospective Randomized Controlled Trial of AJG522 versus Standard PEG + E as Bowel Preparation for Colonoscopy
Table 1
Patient demographics, reasons for colonoscopy, and comorbidities.
Parameter
AJG522*
PEG + E†
Total
Number (%) of cases
32
33
Age (yr)
0.369
Median
60
67
Range
26–82
25–84
Gender, (%)
0.622
Male
16 (50.0%)
16 (48.5%)
Reason for colonoscopy, (%)
0.055
Abdominal pain
2 (6.3%)
4 (12.1%)
Bloody stool
5 (15.6%)
6 (18.2%)
Follow-up after polypectomy
5 (15.6%)
8 (24.2%)
Diarrhea
0 (0%)
3 (9.1%)
Constipation
1 (3.1%)
2 (6.1%)
Tumor screening
3 (9.4%)
4 (12.1%)
Anemia
2 (6.3%)
0 (0%)
Inflammatory bowel disease
12 (37.5%)
4 (12.1%)
Other
2 (6.3%)
2 (6.1%)
Comorbidities, (%)
0.518
Diabetes mellitus
5 (15.6%)
2 (6.1%)
Hypertension
12 (37.5%)
5 (15.2%)
Rheumatoid arthritis
2 (6.3%)
0 (0%)
Chronic kidney disease
1 (3.1%)
0 (0%)
AJG522: the solution contained 100.0 g macrogol 4000, 7.5 g sodium sulfate, 2.7 g sodium chloride, 1.0 g potassium chloride, 4.7 g ascorbic acid, 5.9 g sodium ascorbate, and green apple flavoring per liter; total dose = 2 L. †PEG + E (Niflec): the solution contained 59.0 g macrogol 4000, 5.7 g sodium sulfate, 1.5 g sodium chloride, 0.7 g potassium chloride, 1.7 g sodium bicarbonate, and lemon flavoring per liter; total dose = 2 L.